Mbd4 has been shown to function as a thymine glycosylase, both in vivo (Hendrich and Bird, 1998; Millar et al., 2002) and in vitro (Hendrich et al., 1999) , to mediate the apoptotic response to DNA damage (Cortellino et al., 2003; Sansom et al., 2003b) and to the Fas ligand (Screaton et al., 2003) and to interact with the mismatch repair (MMR) gene Mlh-1 . Mbd4 is also frequently mutated in a large number of MMR-deficient tumours that exhibit microsatellite instability (MSI) (also known as replication error positive (RER þ )). However, despite this evidence, questions remain over the role of Mbd4 as a tumour suppressor as Mbd4 mutations have not been reported in MMR-proficient (RERÀ) tumours (Bader et al., 1999 (Bader et al., , 2000 Riccio et al., 1999) . Mbd4 mutations observed in RER þ tumours are normally monoallelic and are predominantly at the polyadenine tract, and therefore these mutations may simply reflect MSI in these tumours. Alternatively, these mutations may give rise to a truncated protein with a dominant gain of function phenotype.
The most convincing evidence that Mbd4 can act as a modifier of intestinal tumorigenesis comes from the Apc Min/ þ mouse model (Millar et al., 2002; Wong et al., 2002) . Here, we have shown that loss of Mbd4 accelerates tumorigenesis and alters the spectrum of mutation at the wild-type Apc allele in tumours (Millar et al., 2002; Wong et al., 2002) . This is consistent with the role of Mbd4 in suppressing CpG deamination in vivo.
In order to test the hypothesis that loss or heterozygosity of Mbd4 is an important modifier of MMRdeficient tumorigenesis, we have crossed mice deficient in either Msh2 or Mlh1 into an Mbd4-deficient background.
Loss of MBD4 does not increase mutation frequency at the Dlb-1b locus in MMR-deficient animals One hypothesis to explain the observed high level of mutation of Mbd4 within RER þ tumours is that Mbd4 can partially compensate for MMR deficiency, especially given the interaction between Mlh1 and Mbd4. We have therefore analysed as to whether loss of Mbd4 increased the mutation frequency at the endogenous Dlb-1b locus in the intestines of MMR-deficient mice (Figure 1 ). We selected this approach both because it is well validated for assessing mutation frequencies in the context of loss of DNA repair activities (reviewed in Sansom and Clarke, 2000) and because it remains the only approach for scoring mutation frequencies in a physiological setting in situ. In accordance with our previous studies, we observed significant increases in mutation frequency at the Dlb-1b locus in both the Msh2-and Mlh1-deficient backgrounds (Toft et al., 1999; Sansom et al., 2001 Sansom et al., , 2003a . When Msh2À/À Mbd4À/À and Mlh1À/À Mbd4À/À mice were compared to the single nulls, the mutation frequency was significantly higher than the Mbd4À/À mice (Pp0.03, Mann-Whitney), but was unchanged compared to the individual MMR mutants: Mlh1À/À (P ¼ 0.51, n ¼ 5, Mann-Whitney), Msh2À/À (P ¼ 0.24, n ¼ 5, MannWhitney). These results argue that the observed mutation of Mbd4 in MSI/RER þ tumours is not due to the ability of Mbd4 to suppress mutation in the absence of MMR, as this predicts a significantly elevated mutation frequency in the doubly mutant Mbd4À/À MMR-deficient mice.
The Dlb-1 assay showed no significant increase in spontaneous mutation frequency locus in the singly mutant Mbd4À/À mice at either 3 (P ¼ 0.89, n ¼ 4 Mann-Whitney, Figure 2 ) or 8 months (wild-type 11 clones 74 s.d., Mbd4 9 clones 72 s.d., P ¼ 0.66, n ¼ 3, Mann-Whitney). It is therefore clear from this study and previous analyses (Drummond and Bellacosa, 2001; Millar et al., 2002; Wong et al., 2002) that Mbd4 deficiency does not confer a mutator phenotype equivalent to MMR deficiency. Our data differs from earlier studies, in that these have reported small but significant increases in the cII locus in the absence of Mbd4. These small changes lie outwith the sensitivity of the Dlb-1 assay, which was specifically used to identify gross changes in mutation frequency in vivo. Notably, given the high mutation frequencies observed in the absence of functional MMR, any additive increase in mutation frequency as a consequence of Mbd4 deficiency would remain undetectable in both the Big Blue or Dlb-1 assays. However, further studies using the Big Blue background may prove interesting, in that they might identify subtle changes in mutation spectra between the Msh2À/À and the Msh2À/À Mbd4À/À mice.
Loss of MBD4 does not increase tumour onset, spectrum or MSI in MMR-deficient animals
To address the significance of loss of Mbd4 to MMRdeficient tumorigenesis, cohorts of mice deficient for MMR and Mbd4 were aged until they showed signs of disease. Given that loss of Mbd4 is rarely a biallelic event in tumorigenesis, mice that were heterozygous for Mbd4 and deficient for MMR were also used. Crosses were initiated to both Mlh1-and Msh2-deficient strains to allow an assessment of each potential reaction. Previously, we and others have shown that Msh2À/À mice predominantly develop lymphomas (B80%) with a smaller proportion developing intestinal tumours (less than 20%) (Buermeyer et al., 1999; Prolla et al., 1998; Sansom et al., 2001 ). Mlh1À/À-deficient mice differ, in that up to 60% of animal develop intestinal tumorigenesis (Prolla et al., 1998) . Mbd4À/À mice have an apparently normal lifespan and have only been shown to develop neoplasias when crossed onto a tumour prone background (Millar et al., 2002) . Figure 2a shows a Kaplan-Meier plot of survival for Msh2À/À Mbd4 þ / þ , Msh2À/À Mbd4 þ /À and Msh2À/ÀMbd4À/À. No significant differences were observed in survival between the three different cohorts Figure 1 Mutation frequency at the Dlb-1b locus per 10 000 villi. Whole-mount intestines from 3-month-old mice that were 93.75% C57Bl6/J were stained with Dolichos biflorus agglutinin peroxidase (1 : 100, TCS) as described by Winton et al. (1988) . White mutant clones per 10 000 crypts were then scored. No increase was observed in Mbd4-deficient mice compared to wild type. Deficiency of Mbd4 did not significantly increase mutation frequency in the MMR-deficient mice of at least 15 mice (all statistical analyses, PX0.7, log rank). Figure 2b shows a Kaplan-Meier plot of survival for Mlh1À/À Mbd4 þ / þ , Mlh1À/À Mbd4 þ /À and Mlh1À/À Mbd4À/À. No significant differences were observed between the three cohorts (all statistical analyses, PX0.5, log rank). During the time frame of this experiment, no mice became ill in the control cohorts of wild-type (n ¼ 10), Mbd4À/À (n ¼ 10) and Mbd4À/À Msh2 þ /À mice (n ¼ 15). Recent experiments from Cortellino et al. (2003) have shown reduced levels of mismatch proteins in the absence of MBD4, suggesting there may be altered predisposition to tumorigenesis in Mbd4À/À Msh2 þ /À mice. However, at 1 year of age, we saw no evidence in support of this, with no gross acceleration of tumorigenesis in the double mutant at least at this time point. There was also no significant difference in tumour distribution and no increase in the number of intestinal adenoma. In Msh2-deficient mice, 14% developed intestinal adenoma (3/22) and 91% lymphoma (20/22). In Msh2À/À Mbd4 þ /À mice, 13% develop intestinal adenomas (2/15) and 80% lymphoma (12/15). In Msh2À/À Mbd4À/À mice, 10% developed intestinal adenomas (2/20) and 90% lymphoma (18/20). When smaller intestinal lesions were microscopically scored and classified according to the morphological criteria (see Kongkanuntn et al., 1999) , again there were no differences between genotypes (data not shown). No differences were observed in tumour distribution in the Mlh1-deficient cohorts: Mlh1À/À Mbd4 þ / þ : adenoma 32% (6/19), lymphoma 84% (16/19); Mlh1À/ ÀMbd4 þ /À: adenoma 44% (8/18), lymphoma 66% (12/18); Mlh1À/ÀMbd4À/À: adenoma 30% (6/20), lymphoma 75% (15/20). These data show that nullizygosity or heterozygosity for Mbd4 does not effect tumorigenesis in either an Mlh1-or Msh2-deficient environment. This therefore raises questions on the significance of the mutations in MBD4 that have been characterized in human MSI/RER þ colorectal cancer. The data presented here argues that simple loss or reduction in the levels of MBD4 (predicted by a single mutation in Mbd4) would have little impact of tumorigenesis per se. Indeed, the findings are consistent with mutation of MBD4 occurring as a reflection of MSI.
Given previous reports that one mutation of Mbd4 can accelerate MSI, tumours were assessed for instability at four microsatellite loci Toft et al., 2002) . Four microsatellite loci were chosen for analysis: D1Mit4, D7Mit17, D10Mit2 and D14Mit15. Primers sequences and reaction conditions are described in Toft et al. (2002) . Tumours were ascribed to exhibit MSI if one (or more) out of four loci was unstable. These loci were chosen so that we could compare our data to previous murine studies that have yielded MSI rates for MMR-deficient mice between 50 and 75% (Cranston et al., 1997; Toft et al., 2002) . MSI was assessed by comparing normal and tumour PCR products analysed using the Genescant software (Bacon et al., 2000; Toft et al., 2002) . Given the lower frequency of lymphoma in the Mlh1-deficient mice, this was only performed on tumours deficient for Msh2À/À and Msh2À/À Mbd4À/À. Again, no significance differences were observed in MSI with 75% of Msh2À/À Mbd4 þ / þ tumours (6/8) deemed unstable compared to 76% of Msh2À/À Mbd4À/À (13/17). Our data therefore shows no effect of Mbd4 deficiency upon MSI. The study by Bellacosa et al. (1999) used two MBD4 mutants both under the control of a CMV promoter: one defective in its MBD, which caused enhanced MSI and one defective in its endonuclease domain, which did not effect MSI. Hendrich et al. (1999) have previously demonstrated that a truncated form of MBD4 (shorter than the one associated with human tumourigenesis) still retained its methyl-binding activity, and therefore could potentially interfere with the binding of other MBD proteins. Taken together, these studies raise the possibility that the Mbd4 mutants observed in human neoplasia may be gain of function mutations. Although this notion is an attractive one, it should be noted that the human mutation produces a truncated protein at codon 317, and thus would most closely parallel the endonuclease mutant produced by Bellacosa et al. (1999) . Indeed, as yet, there is no evidence that the human mutant MBD4 protein that occurs in cancer has a gain of function.
This study has modelled the importance of nullizygosity and heterozygosity for Mbd4 in the context of MMR deficiency. This parallels human neoplasia where MBD4 mutations are exclusively associated with MMRdeficient tumours. This raised the hypothesis that mutation of MBD4 is required for MMR-dependent tumorigenesis (MSI/RER þ ). Our results show that Mbd4 deficiency (or heterozygosity) imparts no selective advantage on an MMR-deficient tumorigenesis either in terms of increased mutational burden at the Dlb-1b locus or accelerated tumorigenesis. Therefore, these studies definitively rule out a role for Mbd4 deficiency as important modifier of MMR-deficient tumorigenesis.
